About Sutro Biopharma

At Sutro Biopharma we have pioneered a compelling and unique way of discovering, developing and manufacturing therapeutics.  Our focus is aimed primarily on next generation cancer therapeutics — Antibody Conjugates and Bispecific Antibodies. Unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell.

Learn More


Our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify the optimal molecule designed for safety and potency.

Learn More


Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies, and antibody-based therapeutics targeting immuno-oncology pathways.

Learn More

Recent News


Sutro Initiates First Clinical Trial of CD74-Targeting ADC for Lymphoma & Multiple Myeloma Treatment; The First of a New Generation of Precisely Engineered ADCs

SOUTH SAN FRANCISCO, April 26, 2018 — Sutro Biopharma, Inc. has begun dosing patients in its initial clinical trial of its  potential first-in-class.. Read More →

Sutro ADC Effectively Targets Folate Receptor Alpha in Ovarian Cancer Preclinical Research

– Phase 1 Trial Planned for Late 2018 – Company’s First Cell-Free Protein SynthesisDrug for Solid Tumors SOUTH SAN FRANCISCO, April 16, 2018.. Read More →


At Sutro, collaboration drives how we achieve results. By putting the goals of the Company first, we aim to make a difference both as individuals and as part of a team.

Learn More